乳腺癌患者血清内IL-6和CCL-18的表达及临床意义

Expression and clinical significance of IL- 6 and CCL- 1 8 in serum of breast cancer patients

目的:定量检测乳腺癌患者血清内IL-6和CCL-18的表达,并分析其表达与临床病理因素的相关性,以评估IL-6和CCL-18作为乳腺癌诊断和预后指标的可行性。方法:ELISA定量检测来自于58名乳腺癌患者,41名乳腺良性肿瘤患者和30名健康人血清内IL-6和CCL-18的表达。Wlicoxon test检测各组间差异。结果:与健康组相比,肿瘤组IL-6和CCL-18表达水平明显升高,但与良性肿瘤组相比,肿瘤组CCL-18表达水平则处于边界值(P=0.05)。而良性肿瘤组与健康组相比,CCL-18和IL-6的表达水平均明显升高。此外,两种细胞因子的表达水平与病人年龄、肿瘤大小、组织学类型、淋巴结转移及组织学分级均无关。IL-6在ER阳性及发生转移的乳腺癌患者血清内表达明显升高,而CCL-18在晚期乳腺癌患者血清内表达明显升高。结论:IL-6和CCL-18可以用来区别乳腺癌患者和健康人群。IL-6的高度表达可能导致ER阳性乳腺癌患者预后较差,而CCL-18的表达与另一个预后参数Ki67的高表达相关。

Objective：To quantify the expression of IL -6 and CCL - 18 in patients with breast cancer,and ana- lyze the relationship with clinically pathological characteristics. Methods：ELISA was performed to detect the serum from 58 breast cancers,41 benign breast tumors and 30 healthy women. Results：IL -6 and CCL - 18 were dramatic- ally upregulated in breast cancers in comparison with healthy controls, but compared with benign tumors, only CCL- 18 was overexpressed at borderline significance in cancers （P = 0.05 ）. The serum from benign breast cancer patients exhibited also significant higher levels of the two cytockines than normal group. In addition, the cytokines profile was not associated with patient age,tumor size, histopathological type,lymph node status or histological grade. IL -6 was significantly overexpressed in ER - positive and metastasized cancers. CCL - 18 presented a significantly higher ex- pression in advanced stage and highly proliferative carcinomas. Conclusion：IL- 6 and CCL- 18 could clearly distin- guish between women with breast cancers and healthy controls. High expression of IL - 6 seems to result in a poor prognosis for ER - positive cancers. CCL - 18 was related with worse prognosis parameters like high Ki67.